Darbepoetin Alfa for Late-onset Anemia in Neonates with Rhesus Hemolytic Disease.
Indian J Pediatr
; 90(2): 184-186, 2023 02.
Article
en En
| MEDLINE
| ID: mdl-36460815
ABSTRACT
Neonates with Rhesus hemolytic disease can present with anemia beyond 1 wk of age due to bone marrow suppression and low erythropoietin secretion. Erythropoietin stimulating agents (ESA) were tried to manage anemia in these neonates. Darbepoetin alfa (DA) is a long-acting ESA used to treat anemia in premature neonates and in children with chronic kidney disease or on cancer chemotherapy. The authors present their experience of using DA to treat late-onset hyporegenerative anemia in 3 neonates with Rhesus isoimmunization. Darbepoetin alfa 4 mcg/kg was given subcutaneously at a 1-2-wk interval to target hemoglobin of 10-12 g/dL. No adverse effects were observed, and the treated infants had a reduced need for the packed red blood cell transfusions.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Eritropoyetina
/
Eritroblastosis Fetal
/
Hematínicos
/
Anemia
Límite:
Female
/
Humans
Idioma:
En
Revista:
Indian J Pediatr
Año:
2023
Tipo del documento:
Article
País de afiliación:
India